ImmuneID appoints Annalisa D’Andrea as President and Scientific Director
CAMBRIDGE, Mass .– (COMMERCIAL THREAD) – ImmuneID, Inc., a precision immunology company using a proprietary platform to identify and therapeutically target antibody interactions that lead to immune disease, today announced that Annalisa D’Andrea, Ph .D., Has been appointed President and Scientific Director. Dr. D’Andrea brings to ImmuneID more than 25 years of experience in translational research in immunology.
“The addition of Annalisa as President and CSO is an important milestone for ImmuneID as the company applies its platform to identify promising immunological therapeutic targets,” said Stephen Elledge, Ph.D., co-founder of ImmuneID and President of ImmuneID SAB, Lasker Award winner and Gregor Mendel Professor of Genetics and Medicine, Harvard Medical School. “Annalisa’s experience in promoting drug candidates to the clinic will be extremely valuable and I look forward to working with her. ”
“Annalisa brings significant drug development experience that will be extremely valuable as the company works to develop therapeutic candidates to treat patients in a wide range of disease areas, such as oncology, autoimmune diseases, severe allergies and infectious diseases, ”said Christoph Westphal, of the Longwood Fund. , MD, Ph.D., co-founder and executive chairman of ImmuneID.
Dr. D’Andrea’s announcement as President and CSO follows the company’s launch last year with $ 22 million in seed funding led by founding investor Longwood Fund. Funding participants included Arch Venture Partners, Pitango HealthTech, Alta Partners, In-Q-Tel, Xfund, and others. ImmuneID plans to use this funding to develop therapeutic programs in areas such as severe allergies, autoimmunity, oncology and infectious diseases.
“The ImmuneID platform enables rapid and accurate analysis of a patient’s immunologic history and holds great promise for generating information that will elucidate disease patterns and patient responses. This information will guide us in the discovery and development of new therapies related to immune diseases, ”said D’Andrea. “I am delighted to join ImmuneID at this point as we build a talented science team and lead the scientific growth of the company. ”
In addition to his appointment at ImmuneID, Dr D’Andrea joins the Longwood Fund as a Venture Partner.
Previously, Dr D’Andrea was Scientific Director of Kiniksa Pharmaceuticals. Prior to joining Kiniksa, D’Andrea was Vice President and Global Head of Discovery for Immunology and Inflammation at Roche, where she was responsible for the discovery and advancement of several clinical drug candidates. Prior to Roche, she was Executive Director and Section Head of Discovery Biology at SRI International, where she was responsible for developing strategies to advance drugs through discovery and development. Dr D’Andrea received a Bachelor of Science, summa cum laude, from the University of Siena in Italy and a PhD from the University of Florence while training at the Wistar Institute at the University of Pennsylvania.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and target millions of antibody interactions that lead to immune disease. Based on technology developed by scientific founders Stephen Elledge (Harvard), Ben Larman (Johns Hopkins) and Tomasz Kula (Harvard), we use our massively parallel, multiplexed and impartial systems to develop therapies for autoimmunity , severe allergies, oncology and infectious disease. ImmuneID was founded in 2020 by Longwood Fund and is headquartered in Cambridge, MA.